Cyclo Therapeutics (CYTH)
(Delayed Data from NSDQ)
$0.66 USD
-0.02 (-3.06%)
Updated Sep 10, 2024 03:59 PM ET
After-Market: $0.66 0.00 (0.00%) 6:06 PM ET
4-Sell of 5 4
F Value B Growth A Momentum D VGM
Income Statements
Fiscal Year end for Cyclo Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 1 | 1 | 2 | 1 | 1 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 1 | 1 | 1 | 1 | 1 |
Selling & Adminstrative & Depr. & Amort Expenses | 21 | 17 | 16 | 10 | 8 |
Income After Depreciation & Amortization | -20 | -16 | -14 | -9 | -8 |
Non-Operating Income | 0 | 0 | 0 | 0 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -20 | -15 | -14 | -9 | -8 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -20 | -15 | -14 | -9 | -8 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -20 | -15 | -14 | -9 | -8 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -20 | -16 | -14 | -9 | -8 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -20 | -16 | -14 | -9 | -8 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 16.33 | 8.44 | 6.37 | 1.60 | NA |
Diluted EPS Before Non-Recurring Items | -1.23 | -1.83 | -2.24 | -5.60 | NA |
Diluted Net EPS (GAAP) | -1.23 | -1.83 | -2.24 | -5.60 | -7.00 |
Fiscal Year end for Cyclo Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.12 | 0.20 | 0.31 | 0.50 | 0.12 |
Cost Of Goods | 0.01 | 0.01 | 0.02 | 0.04 | 0.02 |
Gross Profit | 0.11 | 0.19 | 0.30 | 0.46 | 0.10 |
SG&A, R&D, and Dept/Amort Expenses | 5.74 | 5.31 | 5.93 | 5.22 | 4.73 |
Income After SG&A, R&D, and Dept/Amort Expenses | -5.63 | -5.12 | -5.63 | -4.76 | -4.63 |
Non-Operating Income | -0.35 | 0.78 | 0.00 | 0.00 | 0.00 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -5.98 | -4.34 | -5.64 | -4.77 | -4.64 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -5.98 | -4.34 | -5.64 | -4.77 | -4.64 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -5.98 | -4.34 | -5.64 | -4.77 | -4.64 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 28.64 | 28.59 | 16.33 | 16.19 | 14.04 |
Diluted EPS Before Non-Recurring Items | -0.21 | -0.15 | -0.23 | -0.29 | -0.33 |
Diluted Net EPS (GAAP) | -0.21 | -0.15 | -0.15 | -0.29 | -0.33 |